

## **SQUEEZE Pilot Trial Supplemental Digital Content**

ClinicalTrials.gov [NCT01973907]

Parker MJ, Choong K, Fox-Robichaud A, Liaw PC, Thabane L, for the Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group.

## Table of Contents

Table S1	Summary of Protocol Versions and Amendments	pg 3
Table S2	Hemodynamic, Clinical and Adverse Event Outcomes	pg 4
Table S3	Study process feasibility outcomes	pg 5
Table S4	Study resource feasibility outcomes	pg 6
Table S5	Study management feasibility outcomes	pg 7
Table S6	SQUEEZE-D secondary feasibility outcomes	pg 8
Table S7	Completeness of pre-randomization fluid and blood product data	pg 9
Table S8	Completeness of post-randomization fluid and blood product data	pg 10
Table S9	Completeness of hemodynamic descriptive data	pg 11
Table S10	Completeness of pre-randomization culture and antimicrobial data	pg 12
Table S11	Completeness of post-randomization culture, antimicrobial and laboratory data	pg 13
Appendix S1	CONSORT checklist for pilot and feasibility trials	pg 14
Appendix S2	Table 1 - Extended. Baseline Characteristics	pg 17

Table S1. Summary of Protocol Versions and Amendments

Protocol Version/Date	Date REB Approved	Key Details
Version 1; 04/04/2013	n/a	Provisional approval - revisions requested by REB
Version 2; 20/05/2013	04/06/2013	Revised protocol received full approval
Version 3; 25/06/2013	03/07/2013	Edits to protocol prior to trial launch
Version 4; 27/10/2013	18/11/2013	Edits to protocol prior to trial launch
<b>RECRUITMENT OPENS Jan 6, 2014</b>		
<b>First Participant Enrolled Jan 7, 2014</b>		
Version 5; 09/07/2014	19/08/2014	Lengthening of time window from 2 to 6 hours within which minimum volume of isotonic fluid bolus therapy can be received (inclusion criteria) Additional Translational study (PERSEVERE) added
Version 6; 25/11/2014	16/12/2014	Approval to add second external site to pilot trial Funding sources (new) added

Table S2: Completeness of Hemodynamic and Clinical Outcome and Adverse Event Data

Outcome	Able to collect, N (%), 95% C.I. (N=51)
<b>Hemodynamic Outcome</b>	
Time to Shock reversal (hours)	49 (96.1%), C.I. 86.5 -99.5%
<b>Complications possibly attributable to fluid overload or third spacing</b>	
Pleural effusion requiring drainage (Y/N)	50 (98.0%), C.I. 89.6 - 100%
Intra-abdominal hypertension (Y/N)	50 (98.0%), C.I. 89.6 - 100%
Highest bladder pressure (mm Hg)	50 (98.0%), C.I. 89.6 -100%
Abdominal compartment syndrome (Y/N)	49 (96.1%), C.I. 86.5 - 99.5%
Soft tissue edema (rank: none, mild, moderate, severe)	51 (100%), C.I. 93.0 - 100%
Pulmonary edema (Y/N)	50 (98.0%), C.I. 89.6 - 100%
Lasix (furosemide) exposure (Y/N)	50 (98.0%), C.I. 89.6 - 100%
Lasix (furosemide) exposure (mg/kg)	50 (98.0%), C.I. 89.6 - 100%
Other diuretics used (Y/N)	50 (98.0%), C.I. 89.6 - 100%
<b>Complications possibly attributable to inotrope/vasopressor use</b>	
Clinical signs of digital or soft tissue ischemia (Y/N)	50 (94.1%), C.I. 89.6 - 100%
Digital ischemia requiring revision amputation (Y/N)	48 (94.1%), 95% C.I. 83.8 - 98.8%
Clinical signs of compromised bowel perfusion (Y/N)	48 (94.1%), 95% C.I. 83.8 - 98.8%
<b>Clinical Course and Procedure Outcomes</b>	
Length of Hospital Stay (days)	48 (94.1%), 95% C.I. 83.8 - 98.8%
PICU admission (Y/N)	51 (100%), C.I. 93.0 - 100%
Length of PICU stay (days)	48 (94.1%), 95% C.I. 83.8 - 98.8%
PELOD score components (Y/N)	49 (96.1%), 95% C.I. 86.5 -99.5%
PELOD-2 score components (Y/N)	49 (96.1%), 95% C.I. 86.5 -99.5%
Data to calculate of Ventilator Free Days (Y/N)	48 (94.1%), 95% C.I. 83.8 - 98.8%
28-day Mortality (Y/N)	48 (94.1%), 95% C.I. 83.8 - 98.8%
Hospital Mortality (Y/N)	48 (94.1%), 95% C.I. 83.8 - 98.8%
Cause of Death (if applicable)	48 (94.1%), 95% C.I. 83.8 - 98.8%
Arterial Line Placement (Y/N)	51 (100%), C.I. 93.0 - 100%
Central Line placement (Y/N)	51 (100%), C.I. 93.0 - 100%
Renal Replacement Therapy (Y/N)	49 (96.1%), 95% C.I. 86.5 -99.5%
Chest tube (Y/N)	50 (98.0%), C.I. 89.6 -100%
Peritoneal Drain (Y/N)	49 (96.1%), 95% C.I. 86.5 -99.5%
Echocardiography performed (Y/N)	51 (100%), C.I. 93.0 - 100%
Patient placed on mechanical circulatory support, such as ECMO, to treat refractory shock (Y/N)	49 (96.1%), 95% C.I. 86.5 -99.5%

PELOD - Pediatric Logistic Organ Dysfunction, ECMO - extracorporeal membrane oxygenation, PICU - Pediatric Intensive Care Unit

Table S3. Considerations related to study process feasibility

Process Feasibility Item	Descriptive finding (N=51)
Time from earliest eligibility to randomization Median (IQR) (minutes) Range (minutes)	23 (9.5, 46) 0-1080
Time from randomization to communication of allocation Median (IQR) (minutes) Range (minutes)	5 (2.5, 10) 1-58
Healthcare team member receiving allocation communication Staff physician Registered Nurse PICU fellow PICU resident	29 (56.9%) 1 (2.0%) 20 (39.2%) 1 (2.0%)
Time from communication of allocation to initiation of study procedures Median (IQR) (minutes) Range (minutes)	2 (1, 5) 0 - 175
Time from randomization to initiation of study procedures Median (IQR) (minutes) Range (minutes)	8 (5, 15) 2 - 177
Protocol acceptability to medical staff Tier 1, N (%) Tier 2, N (%)	51 (100%) 51 (100%)
Protocol Deviations Study procedures not implemented within 1 hr of randomization Any fluid bolus >10 mL/kg (500 mL if >50 kg) administered to participant assigned to fluid-sparing arm Any fluid bolus of 20 mL/kg (1000 mL if > 50 kg) administered to participant assigned to fluid-sparing arm Vasoactive medications not initiated in fluid sparing arm Notification of enrolment sheet not provided Notification not provided within 24 hours	2/51 (3.9%) 6/24 (25%) 3/24 (12.5%) 4/24 (16.7%) 2/51 (3.9%) 14/51 (27.5%)
Protocol violations (with reasons) PICU fellow was asked to approach family to discuss study after hours while child still unstable; research team not consulted	1/51 (2.0%)
Protocol suspensions (with reasons) Protocol suspended while participant in the operating room	6/51 (11.8%)
Protocol Withdrawals (with reasons) Consent for ongoing participation declined	3/51 (5.9%)
Other	Telephone access to randomization system

Table S4. Considerations related to study resource feasibility

Resource feasibility item	Descriptive finding
Daily screening of PICU admitted patients and MET Team activations, including for missed patients	1 hour/day
Realtime screening when study team contacted (per case)	15-30 minutes/case
Randomization, notification of clinical team, implementation of study procedures	1 hour/case
Healthcare staff cooperation with study protocol Yes No	50/51 (98.0%) 1/51 (2.0%)
Ability to perform USCOM assessments as specified per protocol	0
USCOM Equipment failure rate	0
Time to complete consent process	Variable; multiple interactions often required 1.5 hrs/case on average
Time to complete case report form during intervention period	3 hours/case; 2-4 hours typical
Follow-up data collection to 90 days	2 hours/case
Time to complete REDCap data entry from paper CRF	2 hours/case
Study promotion activities: Attend PICU daily Mon-Fri; Visit Emergency Department 3x/week	1.5 hours/week

Table S5. Considerations related to study management aspects of feasibility

Management feasibility item	Descriptive finding
On-call schedule to support 24/7 enrolment	Payment for on-call coverage required Site investigators occasionally needed to provide call coverage
Use of pager to contact research team	Worked well, high reliability
Pager linked to MET team paging waterfall	Resulted in an excessive number of pages for non-sepsis MET team activations
Personnel availability for USCOM assessment	Personnel frequently unavailable when assessment required per protocol
REDCap database	worked well for data entry
Rate of successful data abstraction	Some clinical data of interest not reliably documented e.g. radial pulse quality
Rate of successful data entry	No problems with data entry into REDCap database from paper CRF.
Research Ethics Board review timeline Lead site REB approval  External site REB approval	2 months from initial submission to final approval  Lengthy review process at a single external site; pilot trial completed recruitment to target before external site approval obtained

Table S6. SQUEEZE-D process, resource, management aspects of feasibility

Process Feasibility	Descriptive Finding
Access to study specimen tubes	CPT tubes included in same study package as documents for clinical trial implementation
Specimen collection	Coordinated with clinical bloodwork ordered Sample collected by participant's nurse
Specimen transport for initial processing	Specimen transported to core laboratory with other clinically indicated bloodwork
Initial specimen processing	Core laboratory processed sample and placed in -80 C research freezer within Core lab
Specimen transport from clinical site to research laboratory	Samples shipped on dry ice to research lab at TaARI. Transferred to -80 C research freezer
Specimen storage	Initial storage: -80 C research freezer at McMaster Children's Hospital Core Lab TaARI storage: -80 C research freezer in the laboratory of Drs. Fox-Robichaud and Liaw
Resource Feasibility	
Study specimen form completion	Research staff or investigator typically needed to complete in real-time 24/7; not feasible for main trial
Contemporaneous completion and faxing of SQUEEZE-D requisition to pair with clinical sample	Realtime fax and follow-up by phone-call to Core lab required to ensure clinical sample spun and frozen at -80 C within 1 hour.
Study process time	Not feasible to continue having study staff/investigators call Core Laboratory 24/7
Availability of PICU clinical staff	Sample sometimes not collected when clinical staff (PICU nurses) busy with sick patient
Availability of Core Laboratory staff	Core laboratory staff busy, and staffing further decreased after hours. Prompting required to ensure sample processing.
Time-sensitive sample processing	Processing of fresh sample and placement in -80 freezer time sensitive for cfDNA (must be spun and frozen within 1 hour)
CPT tubes	Commonly available, inexpensive
CPT tube labels	Several specimens lost due to failure of label adherence in -80 freezer
Management feasibility	
Specimen form process	Current process not feasible to continue in main trial; new process required



Table S7. Completeness of pre-randomization fluid and blood product data\*

Pre-randomization Fluid Data	Able to collect, N (%), 95% C.I. (N=51)
<b>Fluid Bolus Therapy</b>	
Date and time of first fluid bolus	51 (100%), C.I. 93.0 - 100%
Normal Saline Fluid Bolus received (Y/N)	51 (100%), C.I. 93.0 - 100%
Normal Saline boluses received (number of boluses)	51 (100%), C.I. 93.0 - 100%
Total volume of Normal Saline as fluid bolus therapy (mL)	51 (100%), C.I. 93.0 - 100%
Ringer's Lactate Fluid Bolus received (Y/N)	51 (100%), C.I. 93.0 - 100%
Ringer's Lactate boluses received (number of boluses)	51 (100%), C.I. 93.0 - 100%
Total volume of Ringer's Lactate as fluid bolus therapy (mL)	51 (100%), C.I. 93.0 - 100%
5% Albumin boluses received (Y/N)	51 (100%), C.I. 93.0 - 100%
5% Albumin boluses received (number of boluses)	51 (100%), C.I. 93.0 - 100%
Total volume of 5% Albumin as fluid bolus therapy (mL)	51 (100%), C.I. 93.0 - 100%
<b>Blood Products</b>	
Red Blood Cells received (Y/N)	51 (100%), C.I. 93.0 - 100%
Total volume of red blood cells received (mL)	51 (100%), C.I. 93.0 - 100%
Platelets received (Y/N)	51 (100%), C.I. 93.0 - 100%
Total volume of platelets received (mL)	51 (100%), C.I. 93.0 - 100%
5% Albumin received as transfusion, not bolus (Y/N)	51 (100%), C.I. 93.0 - 100%
Total volume of 5% Albumin as transfusion, not bolus (mL)	51 (100%), C.I. 93.0 - 100%
25% Albumin received (Y/N)	51 (100%), C.I. 93.0 - 100%
Total volume of 25% albumin received (mL)	51 (100%), C.I. 93.0 - 100%
Fresh Frozen Plasma received (Y/N)	51 (100%), C.I. 93.0 - 100%
Total volume of Fresh Frozen Plasma received (mL)	51 (100%), C.I. 93.0 - 100%
Cryoprecipitate received (Y/N)	51 (100%), C.I. 93.0 - 100%
Total volume of Cryoprecipitate received (mL)	51 (100%), C.I. 93.0 - 100%

\*Data collection for the period 24 hours prior to randomization

Table S8. Completeness of Fluid Intake, Fluid Output, and Fluid Bolus data post-randomization

Fluid data to be collected	Able to collect, N (%), 95% C.I. (N=51)
<b>Fluid Intake</b>	
IV maintenance fluids (mL)	49/51 (100%), C.I. 86.5 - 99.5%
IV total parenteral nutrition (mL)	49/51 (100%), C.I. 86.5 - 99.5%
IV fluid bolus therapy (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Enteral fluid and nutrition (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Red Blood Cells (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Platelets (mL)	49/51 (100%), C.I. 86.5 - 99.5%
5% Albumin as transfusion, not bolus (mL)	49/51 (100%), C.I. 86.5 - 99.5%
25% Albumin (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Fresh frozen plasma (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Cryoprecipitate (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Intravenous Immunoglobulin (IVIG) (mL)	49/51 (100%), C.I. 86.5 - 99.5%
IV medication administration (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Scheduled IV fluid replacement (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Fluids administered in the operating room (mL)	49/51 (100%), C.I. 86.5 - 99.5%
Total fluid intake (mL)	49/51 (100%), C.I. 86.5 - 99.5%
<b>Fluid Losses or Removal</b>	
Urine output (mL)	49/51 (96.1%), C.I. 86.5 - 99.5%
Output from drains (mL)	49/51 (96.1%), C.I. 86.5 - 99.5%
Renal replacement therapy (net fluid removal in mL)	49/51 (96.1%), C.I. 86.5 - 99.5%
Losses as vomit/stool (mL)	49/51 (96.1%), C.I. 86.5 - 99.5%
Total fluid output (mL)	49/51 (96.1%), C.I. 86.5 - 99.5%
<b>Fluid Bolus therapy data for each fluid bolus event</b>	
Fluid bolus administered (Y/N)	49/51 (96.1%), C.I. 86.5 - 99.5%
Fluid bolus volume (mL)	49/51 (96.1%), C.I. 86.5 - 99.5%
Fluid bolus volume (mL/kg) - using patient weight	49/51 (96.1%), C.I. 86.5 - 99.5%
Fluid type (NS, RL, or 5% Albumin as bolus)	49/51 (96.1%), C.I. 86.5 - 99.5%
Justification for fluid bolus form (fluid-sparing arm only)	23/24 (95.8%), C.I. 78.9 - 99.9%

IV - intravenous, NS - 0.9 Saline, RL - Ringer's Lactate

Table S9. Completeness of hemodynamic and related descriptive data

Data to be collected	Able to collect , N (%), 95% C.I. (N=51)
<b>Hemodynamic and related data collected at baseline and every 12-hours</b>	
Highest heart rate (bpm)	49 (100.0%), C.I. 86.5 -99.5%
Systolic blood pressure (mm Hg)	49 (100.0%), C.I. 86.5 -99.5%
Diastolic blood pressure (mm Hg)	49 (100.0%), C.I. 86.5 -99.5%
Mean blood pressure (mm Hg)	25 (49.0%), C.I. 34.8 - 63.4%
Highest central venous pressure (mm Hg)	49 (100%), C.I. 86.5 -99.5%
Lowest central venous pressure (mm Hg)	49 (100%), C.I. 86.5 -99.5%
Central venous catheter location	51 (100%), C.I. 93.0 - 100%
Invasive Mechanical ventilation (Y/N)	51 (100%), C.I. 93.0 -100%
Highest mean airway pressure (mm Hg)	49 (96.1%), C.I. 86.5 - 99.5%
<b>Data related to inotrope/vasopressor use</b>	
Vasoactive medications received (Y/N)	51 (100%), C.I. 93.0 - 100%
First Inotrope/vasopressor infusion administered	51 (100%), C.I. 93.0 - 100%
Inotrope/vasopressor dose data	49 (96.1%), C.I. 86.5 - 99.5%
Dopamine (mcg/kg/min)	49 (96.1%), C.I. 86.5 -99.5%
Dobutamine (mcg/kg/min)	49 (96.1%), C.I. 86.5 -99.5%
Epinephrine (mcg/kg/min)	49 (96.1%), C.I. 86.5 -99.5%
Norepinephrine (mc/kg/min)	49 (96.1%), C.I. 86.5 -99.5%
Phenylephrine (mcg/kg/min)	49 (96.1%), C.I. 86.5 -99.5%
Milrinone (mcg/kg/min)	49 (96.1%), C.I. 86.5 -99.5%
Data to support calculation of Vasoactive Inotropic Score	49 (96.1%), C.I. 86.5 -99.5%
<b>USCOM data</b>	
USCOM study performed at Event-00	4 (7.8%), C.I. 2.2 - 18.9%
USCOM study performed at any timepoint	14 (27.5%), C.I. 15.9 - 41.4%
USCOM study performed for $\geq 50\%$ of required events	1 (2%), C.I. 0.0 - 10.5%
<b>Other</b>	
Steroid administration (IV)	51 (100%), C.I. 93.0 - 100%

USCOM - Ultrasound Cardiac Output Monitor

Table S10. Completeness of pre-randomization culture and antimicrobial therapy data\*

Data to be collected	Able to collect, N (%), 95% C.I. (N=51)
Positive cultures	51 (100%), C.I. 93.0 - 100%
Antimicrobials received	51 (100%), C.I. 93.0 - 100%

\*culture and antimicrobial therapy data collected for the 24-hour period prior to randomization

Table S11. Completeness of post-randomization culture, antimicrobial, and laboratory data

Data to be collected	Able to collect, N (%), 95% C.I. (N=51)
Positive cultures	49 (96.1%), C.I. 86.5 -99.5%
Antimicrobial therapy	49 (96.1%), C.I. 86.5 -99.5%
Laboratory data	49 (96.1%), C.I. 86.5 -99.5%

Appendix S1. CONSORT Checklist for Pilot and Feasibility Trials

**CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\***

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>	1a	Identification as a pilot or feasibility randomised trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	2
<b>Introduction</b> Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	3-4
	2b	Specific objectives or research questions for pilot trial	3-4,7
<b>Methods</b>			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	4
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	10, Table S1
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	7-8
Interventions	4c	How participants were identified and consented	4,8
	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6-7, Figure 1, published protocol
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	Protocol
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	N/A
Sample size	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	7, protocol
	7a	Rationale for numbers in the pilot trial	8
Randomisation:	7b	When applicable, explanation of any interim analyses and stopping guidelines	8
	8a	Method used to generate the random allocation sequence	6
Sequence generation	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	6
	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	6

mechanism			
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	Protocol
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	7-9
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	9, Figure 2
	13b	For each group, losses and exclusions after randomisation, together with reasons	9, Figure 2
Recruitment	14a	Dates defining the periods of recruitment and follow-up	9
	14b	Why the pilot trial ended or was stopped	14
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	Table 2, Table S2-S11
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	Table 2, Table S2-S11
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	Figure 4
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	11
	19a	If relevant, other important unintended consequences	N/A
<b>Discussion</b>			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	14
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	12
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	12-15
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	13-15
<b>Other information</b>			
Registration	23	Registration number for pilot trial and name of trial registry	4
Protocol	24	Where the pilot trial protocol can be accessed, if available	4
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	28
	26	Ethical approval or approval by research review committee, confirmed with reference number	4

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license (<http://creativecommons.org/licenses/by/3.0/>), which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials. Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming; for those and for up-to-date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).



Appendix S2. Table 1 - Extended. Baseline Characteristics

Baseline characteristic	Usual care* (n=27)	Fluid-sparing* (n=24)
Age (months)	94.6 (67.9)	118.9 (58.6)
Male Gender	15 (55.6%)	10 (41.7%)
Weight (kg)	31.2 (27.4)	33.9 (22.0)
Admission diagnosis to hospital	27 (100%)	24 (100%)
Sepsis-related	25 (92.6%)	22 (91.7%)
Not sepsis-related	2 (7.4%)	2 (8.3%)
Location of patient screened eligible		
Emergency Department	7 (25.9%)	15 (62.5%)
Hospital Ward	7 (25.9%)	2 (8.3%)
PICU	13 (48.1)	7 (29.2%)
Previous medical comorbidities	23 (85.2%)	17 (70.8%)
Neurological	10 (43.5%)	11 (64.7%)
Cardiac	5 (21.7%)	2 (11.8%)
Pulmonary	4 (17.4%)	4 (23.5%)
Hematological	5 (21.7%)	8 (47.1%)
Malignancy	5 (21.7%)	4 (23.5%)
Gastrointestinal	6 (26.1%)	6 (35.3%)
Endocrine	3 (13.0%)	6 (35.3%)
Immunodeficiency	1 (4.3%)	1 (5.9%)
Genetic/Hereditary disorder	8 (34.8%)	6 (35.3%)
Renal	5 (21.7%)	4 (23.5%)
Other	3 (11.1)	5 (20.8)
PRISM III Score		
Mean (SD)	10.8 (7.6)	14.5 (9.7)
Median (IQR)	9.0 (5.0, 13.5)	13 (7.5, 18.3)
Heart Rate (beats per minute)	143.5 (26.7)	134.3 (27.3)
Systolic Blood Pressure (mm Hg)	91.8 (13.9)	87.0 (14.6)
Diastolic Blood Pressure (mm Hg)	53.4 (13.3)	48.3 (9.5)
Mean Blood Pressure (mm Hg)	67.0 (10.6); (n=14)	59.7 (8.6); (n=11)
Capillary refill time (seconds)	3 (2, 3); (n=20)	3 (2, 4); (n=16)
Radial Pulse Quality		
Normal	18 (66.7%)	10 (41.7%)
Weak or thready	4 (14.8%)	5 (20.8%)
Bounding	2 (7.4%)	2 (8.3%)
Not available (not documented)	3 (11.1%)	7 (29.2%)
Mental status altered from baseline		
Yes	18 (66.7%)	17 (70.8%)

Respiratory Rate (breaths per minute)	30 (22, 40)	22 (19.5, 31.5)
SpO2 (percent)	97.0 (95.0, 98.5)	98 (97, 99.3)
Body Temperature (degrees Celsius)	37.6 (36.8, 38.4); (n=27)	37.2 (36.9, 37.6); (n=23)
pH	7.34 (7.25, 7.39); (n=23)	7.32 (7.24, 7.41); (n=21)
Lactate (mmol/L)	2.0 (1.5, 3.7); (n=21)	2.9 (1.8, 4.0); (n=19)
Bicarbonate (mmol/L)	22 (17, 24); (n=24)	20 (16, 24); (n=22)
Glucose (mmol/L)	6.6 (5.0, 7.3); (n=21)	6.4 (4.8, 12.4); (n=19)
Potassium (mmol/L)	3.9 (3.3, 4.3); (n=24)	3.7 (3.4, 4.1); (n=21)
Documented positive test for Malaria		
Not tested	27 (100%)	24 (100%)

\*estimates are mean (SD) or median (Q1, Q3) for continuous variables and n (%) for categorical variables.

Variable is available for group n unless otherwise noted.

Pediatric Intensive Care Unit (PICU); Pediatric Risk of Mortality (PRISM); standard deviation (SD); kilograms (kg); millimetre of mercury (mm Hg); interquartile range (IQR), oxygen saturation (SpO2)